ImageneBio, Inc. (IMA NASDAQ) stock market data APIs
$5.0648
0(0%)
as of September 11, 2026
Try our APIs with
free plan!
ImageneBio, Inc. Financial Data Overview
Price chart is built with
Anychart
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Prev. Close
5.0648
Open
5.0575
High
5.1552
Low
4.9058
52 wk Range
3.94-9.2
Market Cap
57 781 K
Shares Outstanding
11 374 K
EPS
-0.63
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ImageneBio, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ImageneBio, Inc. data using free add-ons & libraries
Get ImageneBio, Inc. Fundamental Data
ImageneBio, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -58 366 500
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ImageneBio, Inc. News
New
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
IMAX (IMAX) Corporation announces the opening weekend for Amazon (AMZN) / MGM Studies’ “Project Hail Mary,” with IMAX delivering $28M at the global box office. The latest Filmed For IMAX release...
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
ImageneBio, Inc. Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organiz...
iMarketAmerica Breaks Ground on Gradiant Technology Park Creating a Home for Samsung Suppliers and Companies that Seek a Partnership with Samsung
Taylor, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Leaders from Korea and Central Texas gathered in Taylor last month to mark the groundbreaking of the Gradiant Technology Park (GTP), a 212-acre indus...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to op...
Get ImageneBio, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
